This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Non-Hodgkin's lymphoma (NHL)	Heat shock 105 kDa/110 kDa protein 1 (HSPH1; HSP105)	Studies in mice and patient samples suggest inhibiting HSP105 could help treat B cell NHL. In tumor samples isolated from patients with B cell NHL, HSP105 expression was higher in aggressive cancers than in indolent cancers or normal lymph nodes. In a xenograft mouse model of B cell NHL, an anti-HSP105 antibody decreased tumor volume compared with control IgG. Next steps include developing new anti-HSP105 therapeutic mAbs.	Unpatented; licensing status unavailable	Zappasodi, R. <i>et al. Blood</i> ; published online Aug. 22, 2011; doi:10.1182/blood-2011-06-364570 Contact: Massimo Di Nicola, National Institute of Cancer, Milan, Italy e-mail: massimo.dinicola@istitutotumori.mi.it
<i>SciBX</i> 4(36); doi:10.1038/scibx.2011.1016 Published online Sept. 15, 2011				